Skip to content
PeptideFactSheets
Plain-English comparison

Growth hormone pathway peptides: what readers should understand

How tesamorelin, sermorelin, CJC-1295, and ipamorelin differ in mechanism, status, and evidence.

By the PeptideFactSheets Editorial Team. Use the source links to verify status, evidence, risks, and unknowns; our editorial policyexplains the boundaries. Clinician review appears only when a named reviewer is shown.

The quick overview

These peptides can influence the growth-hormone pathway in different ways, but a shared pathway does not give them shared approval, evidence, or safety.

Tesamorelin has a narrow FDA-approved HIV-lipodystrophy indication. Sermorelin's former approved product is discontinued. CJC-1295 and ipamorelin are not FDA approved and have limited evidence for popular consumer uses.

Side-by-side comparison

Tesamorelin
FDA approved for specific usesStrong human evidence for approved uses

Studied for

HIV-associated lipodystrophy · Visceral abdominal fat · Metabolic measures

Sermorelin
DiscontinuedLimited or unclear evidence

Studied for

Growth hormone secretion testing · Growth hormone deficiency in historical contexts · Growth hormone pathway effects

CJC-1295
Not FDA approvedEarly human evidence

Studied for

Growth hormone and IGF-1 levels · Pharmacology and tolerability

Ipamorelin
Not FDA approvedEarly human evidence

Studied for

Growth hormone release · Gastrointestinal motility · Postoperative ileus

Approved versus investigational

An FDA approval means the agency reviewed evidence for a specific product, population, and use. It does not validate other molecules in the same family or uses outside the label. “In Phase 3” still means investigational.

What researchers are studying

  • Growth hormone and IGF-1 signaling
  • HIV-associated lipodystrophy
  • Historical diagnostic testing
  • Body composition and gastrointestinal research

Risks and reasons for caution

  • Growth hormone and IGF-1 affect many tissues; more signaling is not automatically better.
  • Blood-sugar changes, fluid retention, joint symptoms, and other pathway-related risks may matter.
  • Past approval, a narrow approval, and no approval are three different regulatory states.

What remains uncertain

  • Long-term safety for unapproved wellness uses
  • Whether hormone-level changes produce meaningful functional outcomes
  • Safety and effectiveness of combinations promoted online

Questions to ask a healthcare professional

1. Is there a diagnosed condition and an approved option?

2. Is the goal a laboratory number or a meaningful health outcome?

3. What conditions make growth-pathway stimulation risky?

4. Is the claimed product covered by an approved application?

Plain-English takeaway

Pathway similarity is not clinical equivalence. Tesamorelin's narrow approval does not validate sermorelin, CJC-1295, ipamorelin, or their combinations for anti-aging or body-composition claims.

ComparePeptides for recovery: what evidence exists?What the evidence really says about BPC-157, thymosin beta-4, CJC-1295, and ipamorelin for injury recovery.ComparePeptides for skin and aging: research versus hypeA careful guide to peptide research, cosmetic ingredients, injectable claims, and the slippery word “anti-aging.”ComparePeptides for muscle growth and performance: what human evidence showsWhy growth-hormone signals, mitochondrial biology, and body-composition claims do not automatically prove more muscle, strength, recovery, or performance.

References

  1. 1
    fdaFDA prescribing information: Egrifta SV

    Tesamorelin label covering the narrow HIV-lipodystrophy indication and limitations of use.

  2. 2
    fdaFederal Register: Geref discontinuation determination

    FDA determination that discontinued Geref products were not withdrawn for safety or effectiveness reasons.

  3. 3
    clinical trialsClinicalTrials.gov: CJC-1295 in HIV visceral obesity

    Registered CJC-1295 human study showing the limited clinical context for this pathway.

  4. 4
    pubmedCJC-1295 growth hormone and IGF-1 study

    Early human hormone-response evidence rather than proof of broad clinical benefit.

  5. 5
    pubmedIpamorelin pharmacokinetic-pharmacodynamic study

    Human pharmacology evidence that does not establish anti-aging or body-composition outcomes.